Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ).
Suzhou Basecare Medical Corporation Limited has received approval from the National Medical Products Administration of China for its GEMS series embryo culture medium, specifically the VitBase embryo processing fluid. This approval marks a significant milestone for the company, as it becomes one of the few globally to hold CE, FDA, and TGA certifications for assisted reproductive fluids. The product is based on over 30 years of clinical experience and aims to enhance accessibility and supply chain security in China, positioning the company strongly in the IVF market.
The most recent analyst rating on (HK:2170) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited is a company based in China, operating in the medical industry. It focuses on developing and providing medical products, particularly in the field of assisted reproduction. The company is known for its innovative approach and holds various international certifications for its products.
Average Trading Volume: 405,650
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.02B
See more data about 2170 stock on TipRanks’ Stock Analysis page.